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Abstract
Beta-defensins are antimicrobial peptides produced by several cell types, including respiratory epithelia and
leukocytes. Expression of some beta-defensins is increased by bacterial-induced inflammatory responses
whereas expression of other beta-defensins is constitutive. Two beta-defensins are expressed in lungs of sheep
(sheep beta-defensin-1 and -2; SBD-1/-2) and expression of SBD-1 is increased during parainfluenza virus
type 3 (PI-3) infection. The effect of Mannheimia haemolytica, a Gram-negative bacteria known to induce
expression of bovine beta-defensins and NF-kappa B in lung, has not been determined for SBD-1/-2. In this
study, different concentrations of M. haemolytica were inoculated into pulmonary bronchi of lambs. SBD-1
and SBD-2 mRNA levels detected by real time reverse transcriptase polymerase chain reaction in lung
homogenates did not increase. In fact, SBD-1 mRNA levels were significantly decreased with the highest
administered inoculum concentration (109). In contrast, mRNA levels of interleukin-8 (IL-8) were
significantly increased over controls and progressively increased with M. haemolytica concentrations. Co-
inoculation of M. haemolytica with xylitol, an osmotic agent, did not alter mRNA levels of SBD-1, SBD-2 or
IL-8. SBD-1 mRNA expression was detected in lung epithelia, but not in leukocytes. This study suggests that
SDB-1 expression occurs in epithelia and decreases during severe bacterial pneumonia, which is in contrast to
the increase that occurs with PI-3 infection.
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Abstract
Beta-defensins are antimicrobial peptides produced by several cell types, including respiratory epithelia and leukocytes. Expression of
some beta-defensins is increased by bacterial-induced inflammatory responses whereas expression of other beta-defensins is constitutive.
Two beta-defensins are expressed in lungs of sheep (sheep beta-defensin-1 and -2; SBD-1/-2) and expression of SBD-1 is increased during
parainfluenza virus type 3 (PI-3) infection. The effect of Mannheimia haemolytica, a Gram-negative bacteria known to induce expression of
bovine beta-defensins and NF-kappa B in lung, has not been determined for SBD-1/-2. In this study, different concentrations of
M. haemolytica were inoculated into pulmonary bronchi of lambs. SBD-1 and SBD-2 mRNA levels detected by real time reverse
transcriptase polymerase chain reaction in lung homogenates did not increase. In fact, SBD-1 mRNA levels were significantly decreased with
the highest administered inoculum concentration (109). In contrast, mRNA levels of interleukin-8 (IL-8) were significantly increased over
controls and progressively increased with M. haemolytica concentrations. Co-inoculation of M. haemolytica with xylitol, an osmotic agent,
did not alter mRNA levels of SBD-1, SBD-2 or IL-8. SBD-1 mRNA expression was detected in lung epithelia, but not in leukocytes. This
study suggests that SDB-1 expression occurs in epithelia and decreases during severe bacterial pneumonia, which is in contrast to the increase
that occurs with PI-3 infection.
q 2004 Elsevier Ltd. All rights reserved.
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1. Introduction
Antimicrobial peptides are an integral component of the
innate immune system. Defensins are cationic antimicrobial
peptides produced by a wide range of species and have
microbicidal activity against bacteria, fungi and enveloped
viruses [1–5], including HIV-1 [6]. Alpha-defensins are
produced by paneth cells and leukocytes and beta-defensins
are produced by epithelia and leukocytes [3,5]. Antimicro-
bial activity of beta-defensins can be decreased by high salt
concentrations [4,7–9]; however, recent studies indicate
that osmotic agents such as xylitol may enhance defensin
activity, even in high salt conditions [10]. Over 26 human
beta-defensins have been identified [11,12]. Expression of
some beta-defensins, such as human beta-defensin-1
(HBD-1), is constitutive, whereas expression of other
beta-defensins, such as HBD-2, 3, and 4, [4,8,13], mouse
beta-defensin-2 [14], tracheal antimicrobial peptide (TAP)
and lingual antimicrobial peptide (LAP) of cattle, is
inducible [15–18]. Induction often occurs secondary to
activation of Toll-like receptor 4 (TLR 4) and NF-kappa B
signaling [4,5]. Sheep beta-defensin-1 and -2 (SBD-1 and
-2) are also members of the beta-defensin family. SBD-1 is
developmentally regulated in late gestation through the
neonatal period with maximal expression in trachea, lung
and rumen reached shortly after birth [19–21]. Although
SBD-1 appears to lack NF-kappa B responsive elements,
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SBD-1 expression is increased during infection with ovine
parainfluenza virus type 3 (PI-3) [22]. SBD-2 is also
developmentally regulated and expressed primarily in
the alimentary tract [20,23]; however, only low levels of
SBD-2 mRNA are present in lung relative to SBD-1 [20,23].
Expression of SBD-1 and SBD-2 in response to bacterial
infection has not been determined.
Mannheimia haemolytica is a common respiratory
pathogen of sheep and cattle [24–27]. M. haemolytica can
cause serious outbreaks of acute pneumonia in neonates,
weaned and growing animals as well as adults [24].
Vaccination against M. haemolytica can enhance resistance
to infection; however, these vaccines are not completely
effective [25,26]. Experimentally, M. haemolytica
activates NF-kappa B signaling [15,28] and enhances
expression of two inducible bovine defensins, TAP and
LAP in cattle [16–18].
The purpose of this study was to: (1) determine the extent
to which M. haemolytica infection in sheep alters SBD-1
and -2 gene expression in vivo by real time reverse
transcriptase polymerase chain reaction (real time
RT-PCR), (2) determine if xylitol treatment alters SBD-1
and -2 expression, 3) compare SBD-1 and -2 expression to
interleukin 8 (IL-8), a cytokine known to have increased
gene expression during M. haemolytica pneumonia in the
bovine [29,30].
2. Results
2.1. Gross lesions
Animals inoculated with M. haemolytica developed
characteristic, gross lesions for this agent in sheep at the
site of bacterial deposition. These areas were consolidated
and deep red/blue in color.
2.2. Histopathology
Animals inoculated with M. haemolytica developed
characteristic microscopic lesions for this agent in sheep
at the site of inoculation. Lesions included dense infiltrates
of neutrophils, seroproteinaceous fluid, accumulation of
polymerized fibrin and small amounts of cell debris within
the airways, interlobular septae and lymphatic vessels.
Non-inoculated areas and lungs from control animals lacked
lesions or contained minimal multifocal peribronchial and
peribronchiolar infiltrates of lymphocytes.
2.3. Quantitative plate counts in lung tissue
and bronchoalveolar lavage fluid (BALF)
M. haemolytica was cultured from BALF and lung tissue
from all animals inoculated with M. haemolytica and not
from control animals (Table 1). Numbers of M. haemolytica
in BALF (cfu/ml) increased progressively with increased
concentration of inoculated bacteria and were present at
both 20 min and 24 h post-inoculation (PI). Numbers of
bacteria in lung tissue at 24 h PI (cfu/g tissue) also
increased progressively with increased concentration of
inoculated bacteria.
2.4. IL-8 mRNA levels
IL-8 expression is known to increase during
M. haemolytica pneumonia [29–31]. As expected, mRNA
levels of IL-8 increased with increasing concentrations of
M. haemolytica, and significantly so ðP ¼ 0:03Þ when
compared to controls (Fig. 1). Xylitol treatment did not
alter IL-8 mRNA levels.
Fig. 1. Interleukin-8 (IL-8) mRNA levels (normalized to Ribo 18S) in lungs
of sheep determined by real time RT-PCR. Group 1, controls; Group 2, 106
M. haemolytica; Group 3, 107 M. haemolytica; Group 4, 108 M. haemolytica;
Group 5, 109 M. haemolytica (n ¼ 3/group). IL-8 mRNA levels
progressively increase with increased bacterial concentrations and are
significantly increased in Group 5 versus controls (Group 1).
Table 1
Number of bacteria (Mannheimia haemolytica) isolated from bronchoal-
veolar lavage fluid (BALF) at 20 min and 24 h post-inoculation (PI) and
number of bacteria isolated from lung tissue at 24 h PI
Group
numbera
Inoculumb Log10 bacteria
(cfu/ml þ sem)
in BALF
Log10 bacteria
(cfu/g þ sem)
in lung 24 h PI
20 min PI 24 h PI
1 0 None None None
2 1.9 £ 106 1.5 ^ 0.9 0.9 ^ 0.9 3.6 ^ 0.5
3 2.3 £ 107 2.9 ^ 1.0 2.4 ^ 1.4 2.8 ^ 1.0
4 2.4 £ 108 5.1 ^ 0.2 3.5 ^ 1.1 7.4 ^ 0.9
5 3.2 £ 109 6.7 ^ 0.1 6.4 ^ 0.5 9.6 ^ 0.3
No M. haemolytica was cultured from control animals, and numbers of
isolated bacteria increased as inoculation concentration of M. haemolytica
increased.
a Three animals in Group 1, four animals in Groups 2, five animals in
Group 4 and six animals in Group 5; xylitol and non-xylitol-treated animals
are combined for this table.
b Number of viable M. haemolytica/ml in inoculum (5 cc/animal).
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2.5. SBD-1 and SBD-2 mRNA levels
In contrast to the increase in IL-8 mRNA expression,
mRNA levels of SBD-1 decreased significantly ðP ¼ 0:01Þ
in lambs that received the highest amounts of
M. haemolytica (Fig. 2). Xylitol treatment did not alter
SBD-1 mRNA levels. SBD-2 mRNA levels were not
significantly altered (Fig. 3) in animals inoculated with
M. haemolytica compared to controls. mRNA levels of
SBD-1 and, to a greater extent, SBD-2, were somewhat
variable as seen previously.
2.6. Levels of SBD-1 mRNA in ovine epithelial cells
retrieved by laser capture microdissection (LCM)
SBD-1 mRNA levels in respiratory epithelia were
determined in epithelial cells retrieved by LCM in order
to define the contribution of respiratory epithelia (versus
leukocytes) in SBD-1 expression. By real time RT-PCR
assessment of mRNA isolated from lung epithelial cells
(bronchi) retrieved by LCM, SBD-1 PCR amplification
resulted in linear amplification that was well within the
suggested threshold levels. SBD-1 mRNA levels
were significantly higher than levels observed in lung
homogenates when normalized to the reference signal
(Fig. 4).
2.7. Levels of SBD-1 and IL-8 mRNA in LPS-stimulated
ovine buffy coat cells
In order to determine if circulating leukocytes, which
infiltrate the lung during pneumonia, contribute to SBD-1
and IL-8 expression, mRNA levels were determined in
LPS-stimulated and control buffy coat cells. LPS-treated
cells had roughly three fold increases in raw total RNA
content at 3 and 24 h incubation with LPS as compared to
control cells (which lacked LPS treatment). SBD-1 mRNA
levels were not detectable at 3 and 24 h in buffy coat cells
with or without LPS-treatment. In contrast, IL-8 had robust
expression in both LPS-treated and control buffy coat cells.
IL-8 expression was slightly increased at 3 h in LPS-treated
Fig. 2. SBD-1 mRNA levels (normalized to Ribo 18S) in lungs of sheep
determined by real time RT-PCR. Group 1, controls; Group 2, 106
M. haemolytica; Group 3, 107 M. haemolytica; Group 4, 108
M. haemolytica; Group 5, 109 M. haemolytica (n ¼ 3/group). SBD-1
mRNAlevelsaresignificantlydecreased inGroup5versuscontrols (Group1).
Fig. 3. SBD-2 mRNA levels (normalized to Ribo 18S) in lungs of sheep
determined by real time RT-PCR. Group 1, controls; Group 2, 106
M. haemolytica; Group 3, 107 M. haemolytica; Group 4, 108
M. haemolytica; Group 5, 109 M. haemolytica (n ¼ 3/group). SBD-2
mRNA levels are not significantly altered between groups.
Fig. 4. SBD-1 mRNA levels (normalized to Ribo 18S) in ovine bronchial
epithelium retrieved by laser capture microdissection are detectable and
higher than whole lung homogenate. In contrast, ovine buffy coat cells
lacked SBD-1 mRNA real time signal even after 50 PCR cycles (Fig. 5).
Fig. 5. IL-8 mRNA levels (normalized to Ribo 18S) determined by real time
RT-PCR in ovine buffy coat cells incubated 24 h with lipopolysaccaride
(LPS þ ) or incubated without LPS (LPS 2 ). IL-8 mRNA levels are
mildly increased with LPS incubation. In contrast, ovine buffy coat cells
lacked SBD-1 mRNA levels after 50 PCR cycles with or without LPS
stimulation.
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cells and moderately increased again at 24 h post-incubation
with LPS as compared to controls (Fig. 5). Because SBD-2
levels were nearly undetectable in control and M. hemolytic-
infected lung, and bronchiolar epithelial cells, SBD-2 was
not assessed in buffy coat cells. The lack of SBD-1
expression in buffy coat cells along with the detection of
SBD-1 in LCM retrieved epithelia, suggest that respiratory
epithelia cells, and not leukocytes, are primarily responsible
for SBD-1 mRNA expression in lung.
3. Discussion
Our observed increase in the expression of IL-8 during
M. haemolytica infection in lambs is consistent with similar,
previous findings in cattle [29–31]. M. haemolytica is a
Gram-negative bacteria that causes an intense inflammatory
reaction characterized in the acute stages (first 24 h) by
vascular leakage of protein, polymerization of fibrin, and
dense infiltrates of neutrophils [24]. Virulence factors
released by M. haemolytica include lipopolysaccharide
and capsular polysaccharide (both of which can incite
inflammatory responses) and a leukotoxin that binds the
CD18 subunit of the beta-2 integrins of leukocytes, resulting
in apoptosis/necrosis [24]. The severity of pneumonia can
be reduced with dexamethasone, suggesting that the
inflammatory response induced by M. haemolytica can be
considered excessive [32]. Indeed, several studies have
demonstrated a marked increase in IL-8 and other
inflammatory cytokines including IL-1 and TNF-alpha
during M. haemolytica pneumonia [29–31]. The inability
of xylitol to alter IL-8 mRNA levels was not altogether
surprising since the high numbers of bacteria in inoculate
likely overwhelm any potentially observable localized
effect(s) of xylitol. The expression of IL-8 mRNA in buffy
coat cells suggests that infiltrating leukocytes may
contribute significantly to IL-8 levels detected in whole
lung homogenates. The lack of SBD-1 mRNA expression in
buffy coat cells in combination with the proportionally high
SBD-1 mRNA expression in respiratory epithelial cells
retrieved by LCM suggests that SBD-1 is expressed
primarily by pulmonary epithelia of the lung.
The lack of increase in mRNA levels for SBD-1 and
SBD-2 suggests that these beta-defensins are not responsive
or regulated by the acute inflammatory conditions induced
by M. haemolytica. Additional work is needed to determine
if SBD-1 and SBD-2 expression is affected similarly by
other microbial pathogens and their products. As with IL-8,
xylitol did not alter SBD-1 or SBD-2 mRNA levels.
Although SBD-2 expression was slightly elevated in Groups
3 and 4, SBD-2 expression in these animals was highly
variable, not statistically significant, and occurred at much
higher cycle points during real time RT-PCR (.45 cycles
and often reaches the allowed maximum [50]) than observed
for SBD-1 (,40 cycles) or IL-8 (,32 cycles); suggesting
that SBD-2 mRNA levels are very low in comparison to
SBD-1 or IL-8. In our experience, rare mRNA signals
(cDNA signals which generally appear above the threshold
of detection at 40 cycles and above), when detected by real
time RT-PCR, seem prone to generate variable target
amplification data. Such has been the case with SBD-2
signal in lung—and the reason it cannot be fully interpreted
to any acceptable degree of statistical confidence. However,
in sheep gastrointestinal tract tissues (e.g. ileum, jejunum,
cecum, spiral colon and rectum), SBD-2 expression is much
more abundant [20,23].
The inability for M. haemolytica infection to induce
SBD-1 expression stands in sharp contrast to bovine
defensins, TAP and LAP, both of which are highly
expressed during M. haemolytica pneumonia [15–19].
The lack of SBD-1 expression suggests that signaling
pathways such as NF-kappa B, which is induced by
M. haemolytica pneumonia [15,28], do not induce or
regulate expression; however, the mechanistic basis
underlying the regulation of SBD-1 and SBD-2 requires
further characterization. It is also reasonable that
M. haemolytica may suppresses SBD-1 expression, since
expression of HBD-1 and the cathelicidin LL37 are both
inhibited/reduced during Shigella ssp.-induced bacillary
dysentery and with Shigella spp. infection of cultured
epithelial cells and monocytes [33].
The lack of observable increase in lung SBD-1 mRNA
levels during experimental pneumonia caused by
M. haemolytica is contrary to our findings that demonstrate
increased SBD-1 and surfactant protein A and D mRNA
expression during viral (PI-3) infection [22]. The different
levels of SBD-1 and surfactant protein A and D expression
that occurs in M. haemolytica and PI-3 infections may
influence the degree of clearance/persistence of each of these
pathogens during pneumonia and may also influence
susceptibility/resistance to secondary pathogens. The diver-
gent response of SBD-1 expression as demonstrated by a
decrease with M. haemolytica infection and increase with PI-
3 infection presents an interesting regulatory process
biologically. Other constitutively expressed beta-defensins
include HBD-1 and mouse beta-defensin-1 (MBD-1) [7,9,
34]. Although HBD-1 expression is constitutive, HBD-1
production in some tissues, such as breast, is relatively high
[35] and HBD-1 mRNA levels can increase with certain
infections, which is somewhat analogous to the increased
SBD-1 expression seen with PI-3 infection.
HBD-1 expression occurs in macrophages and the lack of
SBD-1 mRNA expression in buffy coat cells was somewhat
unexpected. The majority of buffy coat cells were
neutrophils and lymphocytes, however, a small number of
monocytes were also present. It is possible that the lack of
SBD-1 mRNA expression by buffy coat cells could be due
to several reasons: (1) the number of monocytes in the buffy
coat samples was too low for significant SBD-1 mRNA
detection, (2) monocytes in the buffy coat may have
different expression characteristics of SBD-1 than
fully differentiated macrophages, even under LPS
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stimulation, and (3) SBD-1 expression may simply not
occur or is limited in resting monocytes and
LPS-stimulated monocytes, but may be increased by other
stimuli (such as viral infection or interferons). Also, because
lung tissues in this study were collected at one time point
(24 h), it cannot be ruled out that defensin expression may
have risen prior to or after this time point.
Levels of SBD-1 and SBD-2 mRNA expression in lung
homogenates were quite variable. We have noted variability
of SBD-1 expression among similar control animals before,
and variable expression is a feature of other beta-defensins as
well. Such inter-animal variability in defensin expression is
not currently understood, but may be simply due in part to
potentially varying amounts of bronchi, bronchiolar and
alveolar epithelium in each whole lung tissue homogenate.
Exposure to small airborne particles from feed grains,
airborne LPS, or subclinical infections with agents such as
PI-3, or slight differences in lung development or age
between animals could also result in alterations in SBD-1
expression.
This work demonstrates differential expression of IL-8
and SBD-1 and SBD-2 during acute M. haemolytica
pneumonia. The decreased SBD-1 expression that occurs
during M. haemolytica pneumonia contrasts sharply with the
increased SBD-1 expression, that occurs with PI-3 infection.
This contrast identifies an interesting and potentially unique
biological regulatory pathway in defensin gene expression.
4. Materials and methods
4.1. Bacterial inoculum
M. haemolytica serotype 1 strain 82-25, was originally
isolated from a sheep with pneumonia. It was grown
overnight on blood agar containing trypticase soy agar with
5% defibrinated sheep blood (Lab Supply Co., Des Moines,
IA) as described [27]. The overnight growth was transferred
to 35 ml of tryptose broth (Difco Laboratories, Detroit, MI)
and incubated at 37 8C for 3 h on a magnetic stirrer.
The culture was centrifuged at 5860g (SS-34 rotor) for
10 min at 4 8C, suspended in 140 mM NaCl, and adjusted
to 0.108 OD at 600 nm in a spectrophotometer
(Coleman model 35, Bacharach Instrument Co.) to contain
approximately 1.0 £ 108 CFU/ml. The bacterial cells in
150 ml of suspension were split and then pelleted
by centrifugation at 10,000g for 10 min at 4 8C and
re-suspended in 300 mOsm saline or 300 mOsm xylitol.
An exact viable bacterial concentration was determined by
standard plate count on blood agar. The inoculum was kept
on ice throughout the procedure.
4.2. Lambs and inoculation
Twenty-seven, 8-month old lambs (approximately 60 kg
each), were housed in isolation rooms and treated by
methods approved by the National Animal Disease Center
Animal Care and Use Committee. In order to assess
the ability of xylitol to reduce microbial viability in situ,
lambs were first randomly assigned to eight groups of three.
Just prior to inoculation, lambs were lightly sedated with
20 mg xylazine (Rompun, Bayer Corp., Shawnee Mission,
KS). A small plastic tube was inserted into the oral cavity
and served as a speculum for inoculation as performed
and described previously [27,36]. A bronchoscope
(Model administered to ease the scope past the larynx.
The tip of the bronchoscope was moved to the dorsum of the
caudal portion of the cranial lobe of the right lung
(pulmonary deposition site) in each animal for deposition
of inocula. After inoculation, the effect of xylazine was
reversed by intravenous injection of 100 mg tolazoline HCl
(Tolazine, Lloyd Laboratories, Shenandoah, IA).
Lambs in Group 1 were saline-inoculated controls ðn ¼
3Þ:Lambs in Group 2 received 106 CFU M. haemolytica ðn ¼
3Þ in 1 ml 300 mM NaCl and 300 mM xylitol ðn ¼ 3Þ;
respectively. Lambs in Group 3 received 107 CFU
M. haemolytica in 1 ml 300 mM NaCl ðn ¼ 3Þ and
300 mM xylitol ðn ¼ 3Þ; respectively. Lambs in Group 4
received 108 CFU M. haemolytica in 1 ml 300 mM NaCl
ðn ¼ 3Þ and 300 mM xylitol ðn ¼ 3Þ; respectively. Lambs in
Group 5 received 109 CFU M. haemolytica in 1 ml 300 mM
NaCl ðn ¼ 3Þ and 300 mM xylitol ðn ¼ 3Þ; respectively.
4.3. Bronchoalveolar lavage (BAL) and necropsy
At 20 min PI, the lungs of all lambs were lavaged five
times with 20 ml saline per lavage, then pooled (100 ml
total). At 24 h PI, all lambs were euthanized with
pentobarbital and exsanguinated. At necropsy, lungs were
evaluated grossly, and affected lobes were lavaged with
100 ml saline. Pieces of tissue were taken from pulmonary
deposition sites, fixed in 10% neutral buffered formalin
solution and processed for histopathologic examination.
Pieces of lung were also collected for quantitative bacterial
culture. Lung sections were scored according to the type of
infiltrate present (lymphocyte, neutrophil, and macrophage),
and according to the extent of necrosis, hemorrhage,
collapse, and fibrosis. Scores ranged from 0 (no changes)
to 4 (most severe changes) in each category. The final score
was a total of the individual scores for each animal (less the
score for lymphocyte infiltrates and degree of collapse).
Lung tissue and diluted BAL fluid were used for
quantitative plate counts of M. haemolytica (Table 1).
4.4. Real time RT-PCR
SBD-1 and IL-8 gene expression were determined by
two-step fluorogenic real time RT-PCR using primers and
probe sequences (Table 2) listed, and according procedures
previously described in our laboratory [15,22]. Briefly,
real time RT-PCR was carried out according to
manufacturer’s specifications using the GeneAmp 5700
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Sequence Detection System (Applied Biosystems). In this
procedure, total RNA was isolated by Trizol following
manufacturer’s directions (Invitrogen) and cDNA was
generated by reverse transcriptase (following Promega and
Applied Biosystems procedural specifications) in a separate
step preceding the fluorogenic real time RT-PCR procedure
(during which ribosomal 18S RNA was used as the
endogenous reference gene).
4.5. Assessment of SBD-1 and SBD-2 expression
in bronchiolar epithelial cells retrieved by laser
capture microdissection
In order to determine if SBD-1 expression occurred in
respiratory epithelia cells or infiltrating leukocytes,
bronchiolar epithelial cells were retrieved by LCM. Briefly,
lung tissue from normal lambs frozen in OCT media (Sakura
Finetek Inc., Torrance, CA) were sectioned at 8 mm in a
cryostat (Leica) and placed onto a glass slide. The sections
were processed as indicated by a commercial kit (Arcturus,
Inc.). Bronchiolar epithelial cells were retrieved under
adequate power and duration settings with a PixCell II
LCM system (Arcturus, Inc.) and placed in a microfuge tube.
Captured cells were lysed and total RNA was isolated with a
commercial kit (PicoPure RNA isolation kit; Arcturus, Inc.).
SBD-1 and SBD-2 mRNA levels were determined by real
time RT-PCR as described previously [15,22] and above.
4.6. Assessment of SBD-1 and IL-8 mRNA levels
in ovine leukocytes (buffy coat)
In order to determine if SBD-1 expression is present in
leukocytes that infiltrate into the lung during pneumonia,
SBD-1 and IL-8 levels were determined in buffy coat cells
isolated from normal lambs. Briefly, blood was collected in
EDTA, complete blood counts were determined, and buffy
coats were obtained by centrifugation and separation using
Histopaque-1083 (Sigma, St Louis, MO). Buffy coat cells
were maintained in RPMI-1640 media with 10% fetal calf
serum, additional (2 mM) L-glutamine and trace amounts of
b-mercaptoethanol. Cells were incubated with 3.6 mg/ml
purified M. haemolytica lipopolysaccharide (LPS) for 3 and
24 h. Control cells lacked LPS treatment. Total RNA was
isolated from floating and trypsin-EDTA harvested cells
using Trizol according to manufacturer’s recommendations
except our modification of using a 16,100g spin for the final
RNA pellet collection (instead of 7500g). SBD-1 and IL-8
mRNA levels were determined by real time RT-PCR as
described previously [15,22] and outlined above.
4.7. Statistical analysis
Statistical analysis was performed using the means of the
three replicate wells for each cDNA sample being analyzed
for the presence of SBD-1, -2 and IL-8 levels normalized to
their respective ribosomal 18S RNA reference (‘house-
keeping’) signals. To determine if there were significant
treatment and time effects, a two-factor analysis of variance
(ANOVA) (SPSS, SPSS Inc., Version 9.0, Chicago, Ill.) was
used on all samples. Frozen lung tissues from all animals
(controls and infected) from both groups were assessed. Real
time RT-PCR mRNA levels were compared for significance
with the Kruskal–Wallis ANOVA.
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